ライフサイエンスコーパス: institutional review board

1 s and Methods This study was approved by the institutional review board.

2 ed by the local animal studies committee and institutional review board.

3 ve HIPAA-compliant study was approved by the institutional review board.

4 r, HIPAA-compliant study was approved by the institutional review board.

5 aining written consent under approval of the institutional review board.

6 nter retrospective study was approved by the institutional review board.

7 ctive case-control study was approved by the institutional review board.

8 s This prospective study was approved by the institutional review board.

9 ere compliant with HIPAA and approved by the institutional review board.

10 nd HIPAA-compliant study was approved by the institutional review board.

11 tudy was HIPAA compliant and approved by the institutional review board.

12 study and meta-analysis was approved by the institutional review board.

13 iant retrospective study was approved by the institutional review board.

14 trospective cohort study was approved by the institutional review board.

15 This study was approved by the institutional review board.

16 comparative study was approved by the local institutional review board.

17 This retrospective study was approved by the institutional review board.

18 was compliant with HIPAA and approved by the institutional review board.

19 ls and Methods The study was approved by the institutional review board.

20 the protocol was approved by the university institutional review board.

21 tional animal care and use committee and the institutional review board.

22 have established tribal health research and institutional review boards.

23 After approval by the institutional review board, 1,022 LNs in the PET/CT exam

24 opensity score-matched study approved by the institutional review board, 16 patients who tested posit

25 Our research was approved by the McGill institutional review board (A04-M47-12B).

26 s and Methods This study was approved by the institutional review board and all participants gave inf

27 This study was approved by the institutional review board and by national government au

28 s and Methods This study was approved by the institutional review board and compliant with HIPAA and

29 is cross-sectional study was approved by the institutional review board and compliant with HIPAA.

30 This retrospective study was approved by the institutional review board and compliant with HIPAA.

31 ter, retrospective study was approved by the institutional review board and compliant with HIPAA.

32 s and Methods This study was approved by the institutional review board and compliant with HIPAA.

33 s and Methods This study was approved by the institutional review board and complied with HIPAA.

34 esign and implementation were overseen by an institutional review board and conformed to HIPAA guidel

35 This retrospective study was approved by the institutional review board and included 38 patients with

36 Materials and Methods Institutional review board and informed consent were wai

37 Walter Reed National Military Medical Center institutional review board and is compliant with HIPAA g

38 Walter Reed National Military Medical Center institutional review board and is compliant with HIPAA g

39 The study was approved by the institutional review board and is Health Insurance Porta

40 Materials and Methods Institutional review board and local ethics committee ap

41 s The study was compliant with HIPAA and the institutional review board and required written consent

42 rk with human stem cells was approved by the institutional review board and the stem cell research ov

43 ngle-center cohort study was approved by the institutional review board and was compliant with HIPAA.

44 is was a retrospective study approved by the institutional review board and was HIPAA compliant with

45 ls and Methods The study was approved by the institutional review board and written informed consent

46 s This prospective study was approved by the institutional review boards and compliant with HIPAA.

47 a sharing, establishing common protocols for institutional review boards and data sharing, creating p

48 thods The study protocol was approved by the institutional review boards and was HIPAA compliant.

49 The study was approved by the institutional review board, and all participants gave in

50 s and Methods This study was approved by the institutional review board, and all participants gave wr

51 s and Methods This study was approved by the institutional review board, and all subjects gave signed

52 prospective study was approved by the local institutional review board, and informed consent was obt

53 This retrospective study was approved by the institutional review board, and informed consent was wai

54 nter retrospective study was approved by the institutional review board, and the requirement for info

55 This retrospective study was approved by the institutional review board, and the requirement to obtai

56 iant retrospective study was approved by the institutional review board, and the requirement to obtai

57 This retrospective study was approved by the institutional review board, and written informed consent

58 s and Methods This study was approved by the institutional review board, and written informed consent

59 ve cross-sectional study was approved by the institutional review boards, and all participants gave i

60 Materials and Methods This is an institutional review board- and U.S. Food and Drug Admin

61 Materials and Methods The study received institutional review board approval and all patients gav

62 and Methods This prospective study received institutional review board approval and fully complied w

63 Materials and Methods With institutional review board approval and Health Insurance

64 Materials and Methods Following institutional review board approval and informed consent

65 After institutional review board approval and informed consent

66 Institutional review board approval and informed patient

67 Materials and Methods This study had institutional review board approval and was HIPAA compli

68 prospective study was HIPAA compliant, with institutional review board approval and written informed

69 Materials and Methods Institutional review board approval and written informed

70 Materials and Methods Institutional review board approval and written informed

71 Institutional review board approval and written informed

72 Materials and Methods Institutional review board approval and written informed

73 Materials and Methods Institutional review board approval and written informed

74 Materials and Methods Institutional review board approval and written informed

75 ion for colorectal liver metastases, whereas institutional review board approval is required before g

76 Materials and Methods In accordance with the institutional review board approval obtained at the two

77 meet investigational new drug submission and institutional review board approval standards.

78 Retrospective analysis was performed with institutional review board approval using data collected

79 Materials and Methods Institutional review board approval was given and patien

80 patient information was accessed; therefore, institutional review board approval was not sought.

81 Institutional review board approval was obtained and inf

82 Materials and Methods Institutional review board approval was obtained and inf

83 Materials and Methods Institutional review board approval was obtained and the

84 Materials and Methods Institutional review board approval was obtained for act

85 Materials and Methods Institutional review board approval was obtained for thi

86 Materials and Methods Institutional review board approval was obtained for thi

87 Materials and Methods Institutional review board approval was obtained for thi

88 Materials and Methods Institutional review board approval was obtained for thi

89 Materials and Methods Institutional review board approval was obtained for thi

90 Institutional review board approval was obtained for thi

91 Institutional review board approval was obtained for thi

92 Materials and Methods Institutional review board approval was obtained for thi

93 Materials and Methods Institutional review board approval was obtained from Le

94 Materials and Methods Institutional review board approval was obtained with wa

95 Institutional review board approval was obtained, and al

96 Materials and Methods Institutional review board approval was obtained, and in

97 Materials and Methods Institutional review board approval was obtained, and in

98 Materials and Methods Institutional review board approval was obtained, and pa

99 Materials and Methods Institutional review board approval was obtained, and th

100 Materials and Methods Institutional review board approval was obtained, with w

101 Institutional review board approval was obtained, with w

102 rmed with a waiver of informed consent after institutional review board approval was obtained.

103 Materials and Methods Institutional review board approval was obtained.

104 Institutional review board approval was obtained.

105 sement program in U.S. Materials and Methods Institutional review board approval was waived, as the s

106 HISTORY: Materials and Methods Institutional review board approval was waived, as the s

107 After institutional review board approval with a waiver of inf

108 Materials and Methods This study received institutional review board approval with waiver of conse

109 ective multicenter HIPAA-compliant study had institutional review board approval, and all participant

110 Materials and Methods This study had institutional review board approval, and informed consen

111 This HIPAA-compliant study had institutional review board approval, and informed consen

112 Materials and Methods This study received institutional review board approval, and patients gave i

113 Materials and Methods The study received institutional review board approval, and patients in the

114 s and Methods This HIPAA-compliant study had institutional review board approval, and the need for in

115 als and Methods This retrospective study had institutional review board approval, and the need to obt

116 After institutional review board approval, participants were e

117 thods After obtaining antemortem consent and institutional review board approval, the authors compare

118 With institutional review board approval, this study retrospe

119 These include delays in gaining Institutional Review Board approval, timeliness of budge

120 With institutional review board approval, we searched our pro

121 nd Methods This retrospective study received institutional review board approval, with a waiver of th

122 Materials and Methods Following institutional review board approval, with waiver of cons

123 s This cross-sectional study was exempt from institutional review board approval.

124 n's prospective database were evaluated with institutional review board approval.

125 healthy volunteers with informed consent and institutional review board approval.

126 bility Act-compliant study was exempted from institutional review board approval.

127 and patient electronic health records after institutional review board approval.

128 iant retrospective study was completed after institutional review board approval.

129 als and Methods This retrospective study had institutional review board approval; written informed co

130 Materials and Methods This study was institutional review board approved and HIPAA compliant.

131 This study was institutional review board approved and HIPAA compliant.

132 This retrospective study was institutional review board approved and HIPAA compliant;

133 nvolved a phantom experiment, followed by an institutional review board approved clinical interventio

134 An Institutional Review Board approved retrospective search

135 The institutional review board approved the study and all pa

136 The local institutional review board approved the study, and all p

137 Materials and Methods The institutional review board approved the study.

138 Materials and Methods The institutional review board approved this cross-sectional

139 Materials and Methods The local institutional review board approved this HIPAA-compliant

140 Materials and Methods The institutional review board approved this prospective Hea

141 Materials and Methods The institutional review board approved this prospective hyp

142 Materials and Methods The institutional review board approved this retrospective c

143 Materials and Methods The institutional review board approved this retrospective H

144 This institutional review board approved this retrospective s

145 Materials and Methods An institutional review board approved this retrospective s

146 Materials and Methods The institutional review board approved this retrospective s

147 Materials and Methods Institutional review board approved this retrospective s

148 Materials and Methods The institutional review board approved this retrospective s

149 The institutional review board approved this retrospective s

150 The institutional review board approved this study and waive

151 Materials and Methods The institutional review board approved this study.

152 This study was retrospective, institutional review board approved, and HIPAA compliant

153 This retrospective study was Institutional Review Board approved, and informed consen

154 Materials and Methods This institutional review board approved, HIPAA-compliant ret

155 In this institutional review board approved-study, a total of 18

156 s This HIPAA-compliant prospective study was institutional review board approved.

157 This retrospective study was institutional review board approved.

158 Materials and Methods The respective institutional review boards approved this HIPAA-complian

159 Materials and Methods The relevant institutional review boards approved this HIPAA-complian

160 Materials and Methods Institutional review boards approved this HIPAA-complian

161 The applicable institutional review boards approved this study, and all

162 rials and Methods This prospective study was institutional review board- approved and HIPAA compliant

163 In this institutional review board-approved and Health Insurance

164 Materials and Methods This was an institutional review board-approved and HIPAA-compliant

165 Materials and Methods In this institutional review board-approved and HIPAA-compliant

166 Materials and Methods This was an institutional review board-approved and HIPAA-compliant

167 th 67 CLMs were enrolled in this prospective institutional review board-approved and HIPAA-compliant

168 Materials and Methods This institutional review board-approved and HIPAA-compliant

169 ee-year period were included randomly in our institutional review board-approved and retrospective st

170 rty consecutive patients were enrolled in an institutional review board-approved clinical trial and r

171 a prospective, multicenter, HIPAA-compliant, institutional review board-approved clinical trial was p

172 astinal lymph node resection (MLNR) under an Institutional Review Board-approved common protocol from

173 Materials and Methods In this institutional review board-approved HIPAA-compliant retr

174 Materials and Methods This institutional review board-approved HIPAA-compliant retr

175 Materials and Methods For this institutional review board-approved HIPAA-compliant retr

176 Materials and Methods In this institutional review board-approved HIPAA-compliant retr

177 terials and Methods This was a retrospective institutional review board-approved HIPAA-compliant stud

178 agnosed HL (n = 19) and NHL (n = 2) onto the Institutional Review Board-approved investigation of (11

179 agnosed HL (n = 19) and NHL (n = 2) onto the Institutional Review Board-approved investigation of (11

180 nosed DIPG were prospectively enrolled on an institutional review board-approved investigational stud

181 An institutional review board-approved multicenter prospect

182 In an institutional review board-approved multicenter study, w

183 ics and outcomes data were obtained from our institutional review board-approved myeloma database.

184 Methods: In an Institutional Review Board-approved pilot study, the ini

185 erials and Methods For this HIPAA-compliant, institutional review board-approved prospective blinded

186 ce of distant metastases were enrolled in an institutional review board-approved prospective clinical

187 ce of distant metastases were enrolled in an Institutional Review Board-approved prospective clinical

188 In this Institutional Review Board-approved prospective cohort s

189 Materials and Methods In this institutional review board-approved prospective observat

190 Methods: In this institutional review board-approved prospective single-i

191 Materials and Methods This was an institutional review board-approved prospective study in

192 aterials and Methods In this HIPAA-compliant institutional review board-approved prospective study in

193 Materials and Methods In this institutional review board-approved prospective study, 2

194 Materials and Methods In this institutional review board-approved prospective study, 4

195 In this institutional review board-approved prospective study, a

196 /pheochromocytoma (MP) were treated using an institutional review board-approved protocol.

197 ollected through the Basque Biobank under an institutional review board-approved protocol.

198 ts (298 cases and 252 controls) according to institutional review board-approved protocols and shippe

199 terials and Methods In this HIPAA-compliant, institutional review board-approved retrospective cohort

200 Materials and Methods An institutional review board-approved retrospective review

201 This study consisted of a HIPAA-compliant institutional review board-approved retrospective review

202 Materials and Methods In this institutional review board-approved retrospective review

203 Materials and Methods This HIPAA-compliant, institutional review board-approved retrospective study

204 Materials and Methods This HIPAA-compliant, institutional review board-approved retrospective study

205 Materials and Methods This HIPAA-compliant institutional review board-approved retrospective study

206 Materials and Methods This institutional review board-approved retrospective study

207 This institutional review board-approved retrospective study

208 Materials and Methods This institutional review board-approved retrospective study,

209 Materials and Methods This was an institutional review board-approved retrospective study,

210 In this institutional review board-approved retrospective study,

211 Methods: In this Institutional Review Board-approved retrospective study,

212 ortability and Accountability Act-compliant, institutional review board-approved retrospective study.

213 This was a HIPAA-compliant, institutional review board-approved retrospective study.

214 from November 2010 to October 2012 for this institutional review board-approved study after they pro

215 icipate in this prospective HIPAA-compliant, institutional review board-approved study between April

216 This institutional review board-approved study from June 2007

217 Materials and Methods This institutional review board-approved study included 125 w

218 Materials and Methods This retrospective institutional review board-approved study included 24 pa

219 Materials and Methods This HIPAA-compliant, institutional review board-approved study measured the p

220 Methods: This was a prospective institutional review board-approved study of 90 patients

221 Methods: This is a prospective institutional review board-approved study of 90 patients

222 This was an institutional review board-approved study of adult patie

223 We performed an institutional review board-approved study of healthy NMD

224 Materials and Methods This retrospective institutional review board-approved study received a wai

225 d Methods This retrospective HIPAA-compliant institutional review board-approved study was exempt fro

226 Materials and Methods This HIPAA-compliant, institutional review board-approved study was performed

227 A prospective, HIPAA-compliant, institutional review board-approved study was performed

228 Materials and Methods In this retrospective, institutional review board-approved study, 120 patients

229 hods In this retrospective, HIPAA-compliant, institutional review board-approved study, 136 consecuti

230 ongitudinal, single-center, HIPAA-compliant, institutional review board-approved study, 157 patients

231 Materials and Methods In this institutional review board-approved study, 20 patients w

232 Materials and Methods In this retrospective, institutional review board-approved study, 33 patients w

233 Materials and Methods In this retrospective, institutional review board-approved study, 41 pediatric

234 In this institutional review board-approved study, a stroke data

235 terials and Methods In this HIPAA-compliant, institutional review board-approved study, all patients

236 Materials and Methods In this institutional review board-approved study, all unenhance

237 t.Materials and Methods: In this prospective institutional review board-approved study, both MUSE DWI

238 rials and Methods This was a HIPAA-compliant institutional review board-approved study, with informed

239 astases were included in this retrospective, institutional review board-approved study.

240 ng with concomitant CT were enrolled in this institutional review board-approved study.

241 informed consent prior to inclusion in this institutional review board-approved study.

242 ening were compared in this HIPAA-compliant, institutional review board-approved study.

243 d patients provided informed consent in this institutional review board-approved study.

244 l patients provided informed consent in this institutional review board-approved study.

245 at 6 months and maintained in a prospective institutional review board-approved study.

246 R) intraoperative OCT study is a prospective Institutional Review Board-approved study.

247 operative OCT Study is a prospective cohort, institutional review board-approved study.

248 enters were enrolled in this cross-sectional institutional review board-approved study.

249 This study was institutional review board-approved with waivers of info

250 This was a retrospective, institutional review board-approved, Health Insurance Po

251 ing from October 2011 to September 2012 with institutional review board-approved, HIPAA-compliant pro

252 This institutional review board-approved, HIPAA-compliant pro

253 Materials and Methods In this binational, institutional review board-approved, HIPAA-compliant pro

254 tudy was a multireader, multi-institutional, institutional review board-approved, HIPAA-compliant ret

255 Materials and Methods This institutional review board-approved, HIPAA-compliant ret

256 Materials and Methods This institutional review board-approved, HIPAA-compliant stu

257 erials and Methods This was a retrospective, institutional review board-approved, HIPAA-compliant stu

258 Materials and Methods In this institutional review board-approved, HIPAA-compliant stu

259 In this institutional review board-approved, HIPAA-compliant stu

260 In an institutional review board-approved, HIPAA-compliant, pr

261 Materials and Methods This institutional review board-approved, HIPAA-compliant, re

262 Materials and Methods This institutional review board-approved, HIPAA-compliant, re

263 In this institutional review board-approved, informed consent-wa

264 f 24 subjects with DME were included in this institutional review board-approved, prospective longitu

265 Materials and Methods This was an institutional review board-approved, prospectively condu

266 This is an Institutional Review Board-approved, retrospective study

267 Materials and Methods SIESTA was an institutional review board-approved, single-center, pros

268 This retrospective HIPAA-compliant study was institutional review board-approved.

269 498484 and NCT00002663) were approved by the Institutional Review Board at Memorial Sloan Kettering C

270 f EHR interventions should be reviewed by an institutional review board, but may not require patient-

271 An institutional review board exemption and a waiver for in

272 Institutional review board exemptions were granted prior

273 s approval was obtained from the centralized institutional review board for this prospective single-a

274 This retrospective study was approved by the institutional review board; informed consent was obtaine

275 nd Methods This research was approved by the institutional review board (IRB) and was HIPAA compliant

276 Institutional review board (IRB) approval was obtained f

277 We validated four prototypes through an institutional review board (IRB)-approved clinical trial

278 essive disorder (TRD) who participated in an Institutional Review Board (IRB)-approved randomised dou

279 We conducted an institutional review board-IRB-approved retrospective re

280 andards in the ethical review of research by institutional review boards (IRBs) due to the rush to en

281 luating the quality and effectiveness of the institutional review boards (IRBs) responsible for overs

282 The institutional review board of Beth Israel Deaconess Medi

283 Cohort Study (HWCS) has been approved by the Institutional Review Board of the Mexican Social Securit

284 tronic health records review approved by the institutional review board of the University Health Netw

285 The study was approved by the institutional review board of Thomas Jefferson Universit

286 This retrospective study was approved by the institutional review board of three institutions.

287 Materials and Methods The institutional review boards of all participating centers

288 Materials and Methods The institutional review boards of each center approved this

289 Materials and Methods The institutional review boards of the four participating ce

290 HIPAA-compliant protocol was approved by the institutional review boards of the participating centers

291 aphy (CT) colonography Materials and Methods Institutional review board permission was obtained to us

292 ns from OLT patients were collected under an institutional review board protocol 2 hours after portal

293 xempt from review by the Columbia University Institutional Review Board, Protocol ID# AAAO3003.

294 priate ICU-based research, investigators and Institutional Review Boards should consider a deferred c

295 iant retrospective study was approved by the institutional review board; the requirement to obtain in

296 The institutional review board waived the need for consent.

297 The institutional review board waived the requirement for in

298 study that were exempted from review by the institutional review board, which consisted of 1007 post

299 This retrospective study was approved by the institutional review board, which waived the requirement

300 rospective multicenter study was approved by institutional review boards with written informed consen